通策醫療(600763.SH)連續第二日跌停 三季度淨利潤同比僅增5.88%
格隆匯10月15日丨繼昨日跌停後,通策醫療今日盤初再度跌停,報價246.65元,市值791億元。公司昨晚公吿,前三季度淨利潤6.2億元,同比增長55.09%,但第三季度淨利潤2.69億元,同比僅增5.88%,而目前通策醫療的市盈率高達110倍。公司三季報還顯示,機構分歧加大。其中,張坤操盤的易方達優質精選(原易方達中小盤混合)悄然消失,中歐醫療健康混合型證券投資基金則繼續增持。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.